Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.2 USD | +0.84% | -3.23% | +14.29% |
03-19 | Aclaris Therapeutics, Inc. Announces Board Resignations | CI |
02-27 | Aclaris Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Business Summary
Number of employees: 89
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Therapeutics
90.3
%
| 25 | 85.2 % | 28 | 90.3 % | +11.27% |
Contract Research
9.7
%
| 17 | 57.2 % | 3 | 9.7 % | -82.15% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 30 | 100.0 % | 31 | 100.0 % | +5.03% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Neal Walker
CEO | Chief Executive Officer | 54 | 30/06/12 |
Kevin Balthaser
DFI | Director of Finance/CFO | - | 31/12/16 |
Ajay Aggarwal
CTO | Chief Tech/Sci/R&D Officer | - | 30/09/21 |
Joseph Monahan
CTO | Chief Tech/Sci/R&D Officer | 68 | - |
General Counsel | - | 31/05/18 | |
James Loerop
PRN | Corporate Officer/Principal | 60 | 30/01/22 |
Elaine Morefield
PRN | Corporate Officer/Principal | - | - |
Corporate Officer/Principal | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Andrew Schiff
BRD | Director/Board Member | 58 | 08/08/17 |
Maxine Gowen
BRD | Director/Board Member | 66 | 01/07/19 |
Andrew Powell
BRD | Director/Board Member | 66 | 24/01/17 |
Director/Board Member | 60 | 06/01/20 | |
Director/Board Member | 57 | 31/08/16 | |
Neal Walker
CEO | Chief Executive Officer | 54 | 30/06/12 |
Anand Mehra
BRD | Director/Board Member | 48 | 31/08/14 |
Director/Board Member | 58 | 31/08/14 | |
Bryan Reasons
BRD | Director/Board Member | 56 | 23/04/18 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 71,264,786 | 69,291,948 ( 97.23 %) | 0 | 97.23 % |
Company contact information
Sector
Sales per Business
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.29% | 85.52M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- ACRS Stock
- Company Aclaris Therapeutics, Inc.